Registration Dossier

Diss Factsheets

Toxicological information

Specific investigations: other studies

Currently viewing:

Administrative data

Link to relevant study record(s)

Description of key information

Additional information

The cardiac sensitization potential of the test item during acute inhalation exposures to dogs was evaluated. Dogs were exposed to concentrations that ranged from 250000 to 500000 ppm (25 to 50%). All five dogs were sensitized by the test substance. The lowest-adverse-effect-concentration for cardiac sensitization is therefore considered to be 250000 ppm.

The ability of the substance to modulate endocrine system was evaluated by conducting 2 in vitro assays:

- Aromatase (Human Recombinant) Assay and Steroidogenesis (Human Cell Line - H295R).

The Aromatase (Human Recombinant) Assay is a screening assay intended to identify chemicals that may affect the endocrine system by inhibiting catalytic activity of aromatase (CYP 19), the enzyme responsible for the conversion of androgens to estrogens. As per the guideline (OPPTS 890.1200) human recombinant microsomes (Human CYP19 Aromatase +P450 Reductase Supersomes), in the three valid independent runs, the mean % aromatase activity was > 83 % at every soluble concentration tested for the test substance, classifying it as a “non-inhibitor”.

The Steroidogenesis (Human Cell Line - H295R) assay was conducted to evaluate the ability of the test substance, trans 1,2-dichloroethylene, to affect the steroidogenic pathway beginning with the sequence of reactions occurring after the gonadotropin hormone receptors through the production of testosterone and estradiol using the human cell line H295R.

According to Steroidogenesis (Human Cell Line - H295R)-US EPA Guideline (890.1550), trans 1,2-dichloroethylene did not inhibit both testosterone and estradiol, therefore is categorized as ‘negative’ for steroidogenic pathway activity based upon the assay results yielded in this test system from three valid, independent runs.